Sermorelin

Sermorelin (GRF 1-29) is a synthetic 29-amino-acid peptide consisting of the first 29 residues of native growth hormone-releasing hormone (GHRH). Those 29 residues contain the complete receptor-binding domain of the 44-amino-acid parent hormone. Sermorelin binds GHRH receptors on pituitary somatotrophs and triggers endogenous growth-hormone release. It was FDA-approved in 1997 for pediatric idiopathic growth hormone deficiency under the brand name Geref.

The molecule was originally developed in the 1980s at the Salk Institute by Roger Guillemin's group, the same laboratory that won a Nobel Prize for characterizing hypothalamic releasing hormones. The truncated 29-residue form preserved full biological activity at the GHRH receptor while being far easier to synthesize than the full 44-residue native hormone. The half-life is approximately 7 to 12 minutes in plasma, which is short compared to the stabilized GHRH analogs that came later.

Geref received FDA approval in 1997 for pediatric idiopathic growth hormone deficiency, with a separate diagnostic indication for evaluating pituitary GH-releasing capacity. The therapeutic indication was for daily subcutaneous injection at doses of approximately 0.03 mg per kg of body weight per day. Adult use was not in the approved labeling. Sermorelin was never FDA-approved for adult GH replacement or for anti-aging indications.

The Clinical Evidence Base

The published clinical evidence for sermorelin sits primarily in three populations.

Pediatric growth hormone deficiency. The FDA approval rested on Phase 3 trials in children with idiopathic GHD. Daily subcutaneous sermorelin produced measurable height velocity improvements and IGF-1 increase in the target population. The trials were the basis for the 1997 approval and the regulatory safety record that compounded sermorelin still references in 2026.

Adult somatopause and off-label adult use. Sermorelin has been used off-label for adult age-related GH decline since the early 2000s. The published evidence base is limited compared with the pediatric program. A 1992 study by Corpas and colleagues in older men aged 60 to 78 reported approximately doubled 12-hour GH release over 6 weeks of treatment. Smaller open-label series have reported subjective improvements in sleep, body composition, and exercise tolerance. No Phase 3 trial has been completed in adult GH deficiency for sermorelin specifically.

Brain tumor research. A 2021 study identified sermorelin as a candidate adjuvant therapy in recurrent glioma, based on signaling effects in tumor cells. This is investigational and outside the established use case for the molecule.

The combined sermorelin trial dataset is smaller than the tesamorelin Phase 3 file but considerably larger than the published evidence for CJC-1295 or ipamorelin. The legacy of FDA approval gives it the strongest regulatory foundation among GHRH analogs used in adult compounding settings.

Sermorelin is the simplest and earliest of the GHRH analogs used clinically. The mechanism is the same as for tesamorelin and CJC-1295: bind the GHRH receptor on pituitary somatotrophs, trigger pulsatile growth-hormone release, and let downstream IGF-1 increase mediate the tissue effects.

The pulsatile pattern is the important detail. Native GHRH is released by the hypothalamus in pulses, roughly every 3 to 5 hours, with the largest pulse coinciding with slow-wave sleep. Sermorelin replicates this pulse pattern when administered as a daily evening injection. It does not produce the sustained supraphysiological GH levels associated with exogenous recombinant human GH. The pituitary feedback loops remain intact, which limits the maximum GH excursion and is the basis for the safety claims that distinguish GHRH analogs from rhGH replacement.

The short 7-minute half-life is sermorelin's main pharmacokinetic limitation compared with newer GHRH analogs. Tesamorelin has a half-life of approximately 30 minutes. CJC-1295 with DAC has a half-life of 6 to 8 days. Sermorelin requires daily injection to produce sustained effect, while the newer molecules can produce comparable GH increase with less frequent dosing.

This compound is on the World Anti-Doping Agency (WADA) Prohibited List. Use in competitive sport, in-competition or out-of-competition, constitutes an anti-doping rule violation.

Pediatric GHD Outcomes

The FDA approval for Geref was based on multi-center trials in children with idiopathic growth hormone deficiency. Daily subcutaneous sermorelin at 0.03 mg/kg/day produced measurable improvements in height velocity (growth rate per year) and increase in serum IGF-1 within the target therapeutic range. The magnitude of the height response was smaller than what recombinant human GH produced in the same population, which is the primary reason pediatric GHD treatment shifted toward rhGH (somatropin) over the following decade and contributed to the commercial decision to discontinue Geref in 2008. The molecule worked in its target population. It was simply outcompeted commercially by direct GH replacement.

Adult Off-Label IGF-1 Response

The most cited adult dataset is the Corpas et al. 1992 study in older men aged 60 to 78. After 6 weeks of daily sermorelin, the 12-hour integrated GH concentration was approximately doubled compared with baseline, with corresponding IGF-1 increase. The magnitude of GH increase was meaningful but did not reach the supraphysiological levels associated with exogenous rhGH. The published adult IGF-1 response across smaller open-label series is consistent with this pattern: typical adult sermorelin protocols produce IGF-1 increases of approximately 20 to 50 percent over 2 to 4 weeks, depending on baseline IGF-1, age, and dose.

The dose-response curve in adults has not been formally characterized in a published trial. Clinical reports suggest most patients reach a plateau in IGF-1 response somewhere between 100 mcg and 300 mcg daily, with higher doses producing diminishing additional response. The plateau exists because the pituitary GH secretion is rate-limited by the amount of GH the somatotrophs can produce and store, not by GHRH receptor activation alone.

Subjective and Body Composition Effects

Adult off-label users and clinicians report several subjective effect patterns, though none has Phase 3 trial-grade evidence.

Sleep quality. Improved depth and continuity of sleep is one of the most commonly reported subjective effects, often appearing within the first week. The mechanistic basis is plausible because GH release is closely linked with slow-wave sleep architecture. Polysomnographic studies in sermorelin-treated adults are limited.

Body composition. Modest reductions in visceral fat and increases in lean mass have been reported in open-label series over 3 to 6 months of treatment. The magnitude is smaller than what rhGH replacement produces and smaller than what tesamorelin documented in HIV lipodystrophy Phase 3 trials. The effects depend heavily on concurrent nutrition and resistance training.

Recovery and exercise tolerance. Subjective reports of improved recovery between training sessions, reduced soreness, and improved exercise tolerance appear in case-series and observational reports. The effects are difficult to separate from the placebo effect in small studies and have not been characterized in controlled adult trials.

Skin and connective tissue. Improved skin elasticity and hair quality are reported in adult cosmetic-medicine settings. The mechanistic plausibility comes from documented GH effects on skin collagen synthesis and follicle biology, but the sermorelin-specific evidence is observational rather than controlled.

The honest summary is that adult sermorelin produces predictable IGF-1 increase of modest magnitude, with downstream subjective and body-composition effects that are biologically plausible but not validated at trial scale.

Approved Pediatric Label Dose

The original FDA-approved Geref label specified 0.03 mg per kg of body weight, administered subcutaneously once daily at bedtime, for pediatric idiopathic growth hormone deficiency. For a 30 kg child, this works out to 0.9 mg (900 mcg) per evening. The bedtime administration timed the GH pulse to overlap with the natural nocturnal pulse during slow-wave sleep, which is the dominant GH-secreting period of the 24-hour cycle. Treatment continued daily until growth plate closure or until the indication for treatment was no longer present.

Adult Off-Label Compounded Dosing

Adult off-label sermorelin from 503A compounding pharmacies uses ranges established in clinical practice rather than in published trials.

Standard adult protocol: 100 to 300 mcg administered subcutaneously once daily, most commonly at bedtime, regardless of body weight. The fixed-dose approach (rather than weight-based) is the typical pattern in adult compounding settings. The 200 mcg dose is the most commonly prescribed and is the basis for most subjective effect reports.

Stack with ipamorelin: Sermorelin can be combined with ipamorelin in the same evening injection. The combination exploits two distinct receptor pathways. Sermorelin activates GHRH receptors. Ipamorelin activates ghrelin receptors. The dual stimulation produces a larger GH pulse than either compound alone, although no controlled trial has tested the specific sermorelin-plus-ipamorelin combination at any defined dose ratio.

Cycling pattern: Many adult protocols use 5-days-on, 2-days-off weekly cycling, or 3-month cycles followed by 1-month breaks. The rationale is to limit potential pituitary receptor desensitization from sustained daily stimulation. No human pharmacokinetic data demonstrates that cycling produces better IGF-1 response than continuous daily use. The cycling rationale is mechanistic and observational rather than evidence-based.

Pharmacokinetics

Sermorelin has a plasma half-life of approximately 7 to 12 minutes after subcutaneous injection. Peak GH response occurs within 30 to 60 minutes of administration and returns to baseline within 2 to 3 hours. The short half-life is what mandates daily injection (or split twice-daily dosing in some adult protocols). The peptide is cleared by proteolytic degradation in plasma. Renal and hepatic clearance pathways are not clinically significant at therapeutic doses.

Steady-state IGF-1 response builds over 2 to 4 weeks of consistent daily injection, as the integrated 24-hour GH exposure increases the hepatic IGF-1 production. Sermorelin discontinuation produces IGF-1 return to baseline within 2 to 3 weeks. The peptide does not accumulate with repeated dosing because of the short plasma half-life, which means dose changes take effect within days rather than weeks.

Administration Technique

The standard injection sites are the abdomen (avoiding the area within 2 inches of the navel), the front of the thigh, and the back of the upper arm. Site rotation prevents injection-site reactions and lipohypertrophy from repeated injection at the same site. Sermorelin is reconstituted in bacteriostatic water from lyophilized powder, typically at a concentration of 1 to 5 mg per vial, with reconstitution volume adjusted to produce a convenient injection volume.

Bedtime administration is preferred because the GH pulse from injection adds to the natural nocturnal GH pulse during slow-wave sleep. Morning or daytime administration produces the same GH pulse but does not amplify the dominant 24-hour pulse. For patients with disrupted sleep schedules, the optimal timing is at least 2 hours before the planned sleep onset and at least 2 hours after the last meal.

Why Adult Sermorelin Dosing Is Not Standardized

Adult dosing of sermorelin is more variable than approved-label pediatric dosing. The Geref pediatric label produced a clear dose-response curve in a clinical population with defined deficiency. Adult off-label use covers a broader range of indications (age-related GH decline, recovery support, body composition, sleep optimization) without a single dose-finding trial that established optimal protocols for any of them. The 100 to 300 mcg range reflects clinical compounding practice rather than controlled trial results. Most clinical protocols titrate based on baseline and post-treatment IGF-1 levels, with a target range typically set at the upper quartile of the age-adjusted normal range rather than at supraphysiological levels.

The pediatric GHD clinical-trial safety record is the cleanest dataset on sermorelin. Reported adverse events at therapeutic doses were generally mild and self-limited. The most common were injection-site reactions (pain, redness, swelling) in roughly 15 percent of pediatric patients. Headache, flushing, and dysgeusia (altered taste) were reported at lower rates. Nausea was occasional.

Adult off-label use has not been studied at the same level of rigor. The expected adverse-event profile based on mechanism includes the same injection-site reactions, mild fluid retention or peripheral edema at higher doses, transient increase in fasting glucose related to GH-induced insulin resistance, and theoretical risk of IGF-1 increase above the age-adjusted upper limit of normal.

Sustained IGF-1 increase is epidemiologically associated with breast, prostate, and colorectal cancer risk in the general population. No sermorelin-specific signal has been documented, but the pediatric trials were not designed to detect this endpoint, and adult use has not been studied at the duration needed to characterize cancer risk. Active malignancy is a contraindication.

Carpal tunnel syndrome and other GH-class adverse events have been reported at low rates in adult off-label use, generally at higher dosing levels.

The three GHRH analogs cover overlapping use cases with different evidence and regulatory profiles.

Sermorelin has the strongest legacy regulatory position (former FDA approval, not on Category 2 list, compoundable). It has the longest pediatric clinical safety record. The short half-life requires daily injection. The adult evidence base is the weakest of the three for any specific indication beyond pediatric GHD.

Tesamorelin has current FDA approval (Egrifta SV and Egrifta WR) for HIV-associated lipodystrophy. The Phase 3 file is the most complete of any GHRH analog. The half-life of approximately 30 minutes supports daily dosing. The off-label use in NAFLD is supported by the Stanley Lancet HIV 2019 trial. It is meaningfully more expensive than compounded sermorelin.

CJC-1295 with DAC has the longest half-life (6 to 8 days), allowing once-weekly dosing. It has no FDA approval. It was placed on Category 2 of the 503A bulks list in 2023. Published human data is limited to small Phase 1 pharmacokinetic studies, most of which were published before the molecule reached commercial availability.

For adult GH optimization in a US compounding setting, sermorelin is the legally cleanest option. For documented visceral fat reduction, tesamorelin is the only molecule with Phase 3 evidence. For extended dosing intervals, CJC-1295 wins on convenience but lacks the clinical-trial backing of the other two.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.